The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PIVOT-006: A phase 3, randomized study of cretostimogene grenadenorepvec versus observation for the treatment of intermediate risk non-muscle invasive bladder cancer (IR-NMIBC) following transurethral resection of bladder tumor (TURBT).
 
Robert S. Svatek
Honoraria - MDxHealth
Consulting or Advisory Role - CG Oncology; Merck; Sanofi Pasteur
Research Funding - FKD Therapies (Inst); JBL (Inst); MDxHealth (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Merck
 
Trinity Bivalacqua
Honoraria - Ferring; Janssen; UROGENE
 
Kirk A. Keegan
Employment - CG Oncology; Janssen Research & Development
Leadership - CG Oncology
Stock and Other Ownership Interests - CG Oncology; Johnson & Johnson/Janssen
Patents, Royalties, Other Intellectual Property - Patent
 
Siamak Daneshmand
Stock and Other Ownership Interests - Taris
Honoraria - Aduro Biotech; Allergan (I); Bausch and Lomb (I); Bristol-Myers Squibb; CG Oncology; Ferring; Janssen Oncology; Johnson & Johnson; Olympus; pacific edge; Pfizer; Photocure; Protara Therapeutics; QED Therapeutics
Consulting or Advisory Role - Ferring; Photocure; QED Therapeutics; Taris
Research Funding - Photocure
Travel, Accommodations, Expenses - Janssen Oncology; Photocure